Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once vs Twice Daily Aspirin in MPN Patients with Aspirin Resistance
NCT06740916Phase 3Recruiting
- Sponsor
- Siriraj Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of aspirin in myeloproliferative neoplasms (MPN) (2 arms), sponsored by Siriraj Hospital. Primary endpoint: Prevalence of aspirin resistance at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
aspirin
03
Conditions
myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT06740916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740916.